- Home
- MHO vs DNLI Comparison
MHO vs DNLI Comparison
Compare MHO & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MHO | DNLI |
|---|---|---|
| Founded | 1976 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.7B |
| IPO Year | 1995 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MHO | DNLI |
|---|---|---|
| Price | $146.52 | $22.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $160.00 | $34.33 |
| AVG Volume (30 Days) | 273.1K | ★ 2.0M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.55 | N/A |
| Revenue | ★ $4,417,781,000.00 | N/A |
| Revenue This Year | $0.66 | N/A |
| Revenue Next Year | $6.97 | $408.85 |
| P/E Ratio | $58.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $116.78 | $12.58 |
| 52 Week High | $163.66 | $27.30 |
Technical Indicators
Market Signals| Indicator | MHO | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 47.83 | 45.25 |
| Support Level | $126.16 | $18.27 |
| Resistance Level | $152.14 | $23.27 |
| Average True Range (ATR) | 4.06 | 1.38 |
| MACD | -1.26 | -0.55 |
| Stochastic Oscillator | 12.91 | 17.96 |
Price Performance
Historical ComparisonAbout MHO M/I Homes Inc.
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprises a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.